Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
about
B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related diseaseCurrent perspectives on the immunopathogenesis of systemic sclerosisTherapeutic Approach to Adult Fibrotic Lung DiseasesManagement of Systemic-Sclerosis-Associated Interstitial Lung DiseaseUpdate on scleroderma-associated interstitial lung diseaseTargeted Therapy in Systemic SclerosisAnimal models of systemic sclerosis: their utility and limitations.Immunology of IgG4-related disease.Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis.Application of the 2013 ACR/EULAR classification criteria for systemic sclerosis to patients with Raynaud's phenomenon.[Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)].Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.Mesenchymal stem cell therapy for refractory scleroderma: a report of 2 cases.Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures PerspectivesLung Infections in Systemic Rheumatic Disease: Focus on Opportunistic Infections.Efficacy and safety of rituximab in rheumatic diseases.Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014.Double heterozygous mice for Klf5 and Fli1 genes: a new animal model of systemic sclerosis recapitulating its three cardinal pathological features.Update on systemic sclerosis.The continuing evolution of targeted therapy for inflammatory skin disease.Recent advances in connective tissue disease related interstitial lung disease.Recent advances in animal models of systemic sclerosis.B lymphocytes in systemic sclerosis: Abnormalities and therapeutic targets.Strategy for treatment of fibrosis in systemic sclerosis: Present and future.Recent advances in managing systemic sclerosis.Interstitial lung disease in systemic sclerosis: current and future treatment.Management of connective tissue diseases associated interstitial lung disease: a review of the published literature.Current and future direction in the management of scleroderma.Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis.Recent advances in the management of juvenile systemic sclerosis.Systemic sclerosis with anti-RNA polymerase III positivity following silicone breast implant rupture: possible role of B-cell depletion and implant removal in the treatment.Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies.Extrahepatic Manifestations of Primary Biliary Cholangitis.Intracellular B Lymphocyte Signalling and the Regulation of Humoral Immunity and Autoimmunity.New treatment directions for IPF: current status of ongoing and upcoming clinical trials.Dramatic improvement of anti-SS-A/Ro-associated interstitial lung disease after immunosuppressive treatment.Epithelial Fli1 deficiency drives systemic autoimmunity and fibrosis: Possible roles in scleroderma.[Pulmonary fibrosis in rheumatic diseases].Scleroderma-related interstitial lung disease.Rituximab in early systemic sclerosis.
P2860
Q24658641-F0B1032E-C8FD-4700-A320-1E218C3D8655Q26741264-FD739064-EE3D-4EB0-8AE7-22851BF1C2A1Q26741569-77CB8D50-4F99-4ACD-9976-F084AFC6383CQ26799573-690B316D-9E78-44E7-A3CD-3ED231DF63F1Q27016132-E3538E85-86A4-4090-A7F8-00DD00F7C398Q28072943-BACE4EF4-18D1-49AA-B196-5D10E1B1CFA6Q28390528-4816DF73-F5F7-4800-B715-406CE3A2427FQ34471314-4FFAED15-0C8A-4435-9C3A-5800966E4D0BQ34721223-D96D8653-7EA8-4053-936D-96D400C4A226Q35257267-891CC04F-DAEE-4FAB-924D-E634307360ECQ36394613-6B409FFD-5514-47EF-BE81-B984E5B6E975Q36975931-DF4E2F29-AEC7-483E-96A0-3D2BC03E7B24Q37345076-2A8D3235-C87A-46CB-9F61-1A3B1F8E4252Q37381549-D8618044-256C-4559-A4E7-BA777A0226E5Q37690737-8DD5D540-68A6-4241-9540-F846A6173F8EQ38353577-F81C1E3C-91D5-4391-B1FF-E11F63193DC9Q38379767-A9B2C7E2-AF9B-4BE6-9E57-423D96323A59Q38489606-998340B3-F4D0-46D3-A603-64020AC6C1C7Q38542317-11AEE313-2F37-4D5A-8EE1-E3E5A179F98EQ38596134-D1F54C91-2D69-4184-B0F4-62C62BF35CACQ38678939-2752683D-EDCA-4332-BB4B-A276AAB8D670Q38701983-BC145B10-74A2-43CE-8698-C7F8FF1C1B7FQ38701988-C4222007-F449-4B15-B35C-72200118A367Q38701990-74415EC8-7D60-4D6F-8984-CFF468F40E5BQ38759138-7CFBB3B0-11C0-4BB0-927E-5CBAF25990DDQ38773637-F1D5F3C2-6492-4D82-8ED3-CF4F8BD3A3EEQ38793513-D3A76CB2-2192-40D2-9437-17FD2CBCA06EQ38823948-F8C7994A-BE74-4C50-8437-BF25129DABC3Q38956376-083E642C-5ADF-4957-A43B-7D7400430F77Q38969038-D6165320-3503-4BAA-9294-F3605F3F8805Q38979780-8AF0F5C9-7651-49D9-829E-EA0C78BF4D73Q39100810-07E79EB2-17AF-47CC-8B9B-78FCB0906545Q39177903-99C2578F-61EE-403F-922D-32AF92DAA8E1Q39272758-DA51BB92-FD9E-4859-9F56-5A4F996079D5Q39330304-1F566B14-4591-430E-A4B8-F26AF3D43BCBQ39883870-27047064-A462-4961-B3DA-FF2A6B541498Q40321155-B39189D1-B078-491D-BB4B-00E4F22BAFDBQ40543288-F42D6BD3-8265-4BF4-8AAF-EC960E4ABAFEQ41105228-BB331BDC-F583-41CD-AEB3-2199AC9E3992Q41544232-45B7C60B-588C-4782-985A-A4C49589F01D
P2860
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Effects and safety of rituxima ...... l and Research (EUSTAR) group.
@en
Effects and safety of rituxima ...... Scleroderma Trial and Research
@nl
type
label
Effects and safety of rituxima ...... l and Research (EUSTAR) group.
@en
Effects and safety of rituxima ...... Scleroderma Trial and Research
@nl
prefLabel
Effects and safety of rituxima ...... l and Research (EUSTAR) group.
@en
Effects and safety of rituxima ...... Scleroderma Trial and Research
@nl
P2093
P2860
P1476
Effects and safety of rituxima ...... l and Research (EUSTAR) group.
@en
P2093
Britta Maurer
Dörte Huscher
EUSTAR Rituximab study group
Jacob M van Laar
Jörg H W Distler
Oliver Distler
Suzana Jordan
Yannick Allanore
P2860
P304
P356
10.1136/ANNRHEUMDIS-2013-204522
P407
P577
2014-01-17T00:00:00Z